Physician intended to use a nanocross elite pta balloon during treatment of a calcified lesion in the patient¿s superficial femoral artery (sfa).Moderate vessel calcification is reported.Artery diameter reported as 5mm.A 0.014 guidewire was used.There was no damage noted to the product packaging prior to use.Ifu was followed and the device was prepped without issue.The device was passed through a previously deployed stent for post dilation.It is reported that a balloon burst occurred during inflation at a pressure of 14atm.It is reported the balloon could not deflate.The balloon could not deflate, so the physician used negative pressure.The balloon took 15 minutes to deflate, as it was a long and tough cto and the distal end got stuck and caught in the sheath.Two additional nanocross elite pta balloons which were prepped as per ifu were attempted to be used but could not be deflated at the lesion site.All components of all devices were removed from the patient with no intervention required.The deflation issues are reported to have caused thrombosis.No further injury reported.
|
Product analysis: the device was received coiled inside shelf carton in bio-hazard bag.The lot number was verified by the outside shelf carton and additionally the device lot number was scanned on the strain relief and confirmed as b068697.No ancillary devices or cine images from the procedure were received for evaluation.Device was decontaminated with cidex opa solution soak and tergazyme soak.The device could not be flushed as the guidewire lumen was blocked, most likely with biologics.A 0.014¿ guidewire was loaded through the tip and but could only be loaded approximately 43 cm into the catheter due to the lumen blockage.An indeflator with pressure gauge was used to inflate the balloon to nominal pressure of 8 atm and then inflate to rbp of 14 atm.Negative pressure was applied to the balloon and the balloon deflated in 10 seconds.3 images were received from the customer related to the device lot numbers and delivery information.Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|